|
|
 |
|
Viewing report
|
|
|
|
Big Pharma Embraces Pharmacogenomics - But Are We There Yet?
Decision Resources, Inc., Aug 2006, Pages: 31
Pharmacogenomics will revolutionize the drug industry by linking the right drug to the right patient. Several companies and regulatory agencies are leading the charge to implement this approach of developing targeted medicines. PGx’s integration is inevitable; pharma companies must get on board now or risk being left behind.
Get the Answers You Need to Shape Your Strategy
Big pharma companies have become increasingly interested in PGx. These companies realize that PGx offers a way to develop better and safer drugs. Which companies are leading the charge to integrate PGx into drug discovery and development?
Appropriate genetic markers and well-documented patient samples are critical to determining disease correlations. How are companies obtaining this information, and how are they using it to create personalized medicines?
Scope of this title:
- PGx leaders: review of companies that are leading the implementation of PGx.
- Patient populations: examples of well-documented patient samples used to determine disease correlations.
- PGx in practice: ways companies are currently using PGx in drug development, patient segmentation, drug dosing, and postmarketing.
- Remaining challenges: review of regulatory, ethical, reimbursement, and legal hurdles that companies must overcome.
- Spectrum Expert Commentaries: an official with the FDA and Decision Resources’ principal director for epidemiology share their insights.
Customers who bought this item also bought
The Pharmacogenomics Outlook
The Role of Pharmacogenomics in Personalized Medicine
Big Pharma Turns to Biologics for Growth to 2010: Financial and Strategic Segmentation of the Big Pharma Sector by Drug Technology
Mitsubishi Pharma Corporation Deals Briefing
Astellas Pharma Inc Deals Briefings
Changing Market Dynamics Fuel the Evolution of Specialty Pharma
Dainippon Sumitomo Pharma Deals Briefing
UCB Pharma Deals Briefing
|
|
|
|
